allogen
hematopoiet
stem
cell
transplant
allohsct
result
signific
morbid
mortal
abil
assess
potenti
sever
rvi
import
manag
patient
review
case
rvi
allohsct
recipi
explor
predict
valu
immunodefici
score
index
isi
establish
respiratori
syncyti
viru
rsv
applic
rvi
caus
respiratori
virus
rvi
occur
yearround
tropic
transplant
center
peak
middl
end
year
ninetyf
recipi
develop
total
episod
rvi
give
cumul
incid
month
month
first
episod
rvi
rsv
influenza
rhinoviru
parainfluenza
common
virus
pneumonia
occur
adenoviru
influenza
rsv
rvi
episod
respect
also
nonneglig
benign
virus
coronaviru
rhinoviru
nineteen
episod
viral
pneumonia
requir
mechan
ventil
death
occur
within
week
rvi
receiv
oper
characterist
analysi
show
isi
predict
pneumonia
posit
predict
valu
rvi
caus
rsv
influenza
adenoviru
parainfluenza
predict
coronaviru
rhinoviru
isi
use
aid
decisionmak
clinic
consult
patient
present
symptom
suggest
rvi
immunodefici
score
index
pneumonia
respiratori
viru
infect
viral
pneumonia
caus
respiratori
virus
rv
nonneglig
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
allohsct
among
respiratori
viral
infect
rvi
caus
respiratori
syncyti
viru
rsv
influenza
human
parainfluenza
viru
hpiv
associ
higher
risk
progress
pneumonia
mortal
howev
clinic
cours
rvi
depend
type
viru
also
immunolog
statu
host
sever
seri
identifi
risk
factor
proxim
transplant
tcell
deplet
cord
blood
mismatch
transplant
presenc
graftversushost
diseas
gvhd
use
glucocorticoid
lymphopenia
predict
poorer
outcom
immunodefici
score
index
isirsv
develop
allohsct
patient
rsv
infect
high
score
predict
progress
upper
respiratori
tract
infect
urti
pneumonia
need
ventil
mortal
recent
isi
shown
applic
influenza
infect
well
significantli
higher
incid
pneumonia
highscor
vs
lowscor
group
studi
retrospect
review
allohsct
recipi
center
respiratori
symptom
posit
polymeras
chain
reaction
pcr
result
rv
primari
aim
studi
evalu
applic
isirsv
retrospect
cohort
allohsct
recipi
rvi
includ
nonrsv
rvi
secondari
aim
describ
epidemiolog
rvi
allohsct
recipi
transplant
center
tropic
infect
tend
occur
yearround
current
avail
literatur
larg
origin
center
temper
climat
retrospect
review
patient
underw
allohsct
hospit
decemb
march
electron
medic
record
patient
review
rv
pcr
perform
episod
pcrproven
rvi
score
use
isirsv
neutrophil
lymphocyt
score
age
year
score
abl
condit
gvhd
corticosteroid
use
prior
day
preengraft
within
day
hsct
score
total
score
transplantrel
inform
treatment
outcom
collect
patient
follow
till
may
death
whichev
earlier
retrospect
analysi
approv
hospit
institut
review
board
made
slight
modif
publish
definit
urti
pneumonia
analysi
outcom
patient
treat
specif
antivir
drug
oseltamivir
ribavirin
treatment
consid
delay
initi
day
diagnosi
overal
surviv
estim
use
kaplanmei
approach
cumul
incid
first
rvi
episod
plot
death
compet
risk
fisher
exact
test
use
investig
associ
isirsv
risk
group
low
moder
high
outcom
measur
includ
incid
pneumonia
subsequ
progress
pneumonia
need
ventil
mortal
rvi
episod
involv
rsv
influenza
hrhv
hpiv
hcov
adv
receiv
oper
characterist
roc
analysi
conjunct
logist
regress
use
assess
isirsv
predictor
pneumonia
infect
caus
abovenam
virus
total
patient
underw
allohsct
studi
period
adult
patient
year
age
among
patient
manifest
rvi
underw
rv
pcr
test
least
one
posit
pcr
result
thirtyon
allohsct
recipi
never
rvi
manifest
undergo
rv
pcr
test
tabl
show
transplantrel
characterist
three
group
patient
rvi
occur
sporad
throughout
year
peak
junejuli
decemberjanuari
see
figur
distribut
type
rvi
across
month
year
mix
infect
two
virus
three
virus
detect
sampl
tabl
show
distribut
clinic
associ
viru
cumul
incid
develop
first
episod
rvi
day
transplant
month
month
year
post
hsct
figur
rvi
episod
episod
manifest
pneumonia
present
episod
initi
manifest
urti
subsequ
progress
pneumonia
give
total
episod
pneumonia
shown
tabl
potenti
virul
virus
rsv
influenza
adv
associ
high
incid
pneumonia
episod
respect
howev
note
even
seemingli
benign
virus
hcov
hrhv
also
associ
nonneglig
incid
pneumonia
episod
respect
expect
influenza
rvi
consist
treat
twentysix
influenza
episod
treat
oseltamivir
two
untreat
episod
one
patient
diagnos
mani
day
urti
symptom
treatment
deem
use
present
acut
respiratori
failur
septic
shock
caus
bacteri
process
throat
swab
return
posit
influenza
posthum
episod
influenza
present
pneumonia
diagnosi
influenza
urti
episod
present
progress
pneumonia
whether
oseltamivir
prevent
progress
pneumonia
analyz
except
episod
treat
case
progress
pneumonia
present
urti
oral
ribavirin
use
treat
episod
rsv
tabl
deem
directli
attribut
viral
pneumonia
includ
rsv
hpiv
primari
caus
death
death
within
week
document
rvi
occur
n
context
multipl
activ
complic
gvhd
neutropen
sepsi
copathogen
multiorgan
failur
instanc
extent
rvi
contribut
toward
death
difficult
ascertain
therefor
surpris
differ
surviv
observ
among
patient
pcrproven
rvi
patient
pcrneg
patient
never
rvi
figur
primari
object
explor
applic
isirsv
rvi
analyz
data
patient
pcrproven
rvi
appli
isirsv
base
isirsv
episod
classifi
low
risk
score
moder
risk
score
high
risk
score
use
fisher
exact
test
isirsv
risk
score
show
signific
associ
pneumonia
rvi
rsv
influenza
hcov
adv
tabl
associ
found
hrhv
hpiv
aboveobserv
associ
explor
prognost
valu
isirsv
rvi
episod
roc
analysi
studi
explor
applic
isirsv
allohsct
patient
rvi
caus
broad
rang
differ
virus
review
data
also
gener
first
time
inform
rvi
patient
tropic
center
main
thrust
studi
see
isirsv
appli
rsv
nonrsv
rvi
predict
valu
advers
outcom
find
ppv
npv
isirsv
predict
pneumonia
cutoff
valu
respect
rsv
influenza
adv
hpiv
practic
relev
exampl
patient
urti
symptom
high
isirsv
seen
clinic
prudent
lower
threshold
chest
xray
find
isirsv
predict
valu
nonrsv
rvi
wholli
surpris
compon
index
shown
individu
risk
factor
advers
outcom
differ
studi
infect
differ
rvi
lymphopenia
exampl
emerg
risk
factor
advers
outcom
sever
studi
steroid
independ
risk
factor
progress
pneumonia
review
hpiv
infect
allohsct
recipi
absenc
virusspecif
factor
index
give
potenti
applic
beyond
rsv
inde
group
develop
isirsv
found
similarli
use
appli
allohsct
patient
influenza
modest
number
patient
adv
hpiv
rvi
observ
similar
pattern
two
virus
well
immunodefici
score
indexrsv
found
predict
pneumonia
hrhv
hcov
seri
could
result
inadequ
number
case
rel
lack
opportunist
potenti
two
virus
even
immunocompromis
patient
hrhv
commonest
caus
common
cold
well
common
viru
found
allohsct
recipi
patient
taken
serious
seri
also
review
data
treatment
outcom
rsv
influenza
controversi
exist
use
oseltamivir
influenza
immunocompet
person
adenoviru
parainfluenza
influenza
pneumonia
present
pneumonia
present
episod
influenza
urti
progress
pneumoniathi
skew
present
prevent
us
studi
use
oseltamivir
prevent
progress
pneumonia
rsv
rsv
pneumonia
allohsct
recipi
associ
signific
mortal
systemat
review
conclud
ribavirin
aerosol
oral
intraven
probabl
benefici
data
fail
show
earli
treatment
within
day
posit
pcr
result
could
prevent
progress
pneumonia
howev
could
result
select
bia
untreat
patient
outpati
well
symptom
mani
day
use
oral
oppos
aerosol
ribavirin
unavail
local
could
caus
failur
prevent
progress
made
observ
analysi
epidemiolog
influenza
rsv
known
differ
tropic
temper
area
singapor
influenza
rsv
occur
yearround
small
peak
junejuli
decemberjanuari
period
correspond
southern
northern
hemispher
winter
respect
data
consist
trend
rvi
occur
sporad
yearround
cohort
patient
figur
also
note
incid
rvi
hsct
report
literatur
differ
greatli
among
studi
suspect
relat
larg
diagnost
method
martino
et
al
use
cultur
method
diagnos
rvi
pcr
metapneumoviru
found
rate
period
furthermor
report
make
mention
coronavirus
wolfromm
et
al
use
multiplex
pcr
report
hsct
patient
develop
rvi
cumul
incid
use
pcr
kit
detect
rang
virus
akin
ambriosini
et
al
found
incid
upper
respiratori
sampl
survey
figur
almost
like
therefor
incid
rvi
unusu
high
studi
limit
absenc
prospect
protocol
confid
complet
captur
case
nevertheless
two
oper
factor
enabl
high
captur
rate
geograph
small
loss
followup
rariti
hsct
patient
advis
return
directli
outpati
clinic
problem
aris
inhous
guidelin
close
follow
give
us
confid
attribut
symptom
viral
infect
also
low
threshold
test
rv
singl
symptom
eg
coryza
trigger
one
problem
struggl
definit
rvi
caus
death
mainli
littl
guidanc
avail
literatur
adher
publish
remain
concern
publish
statement
lack
stringenc
summari
review
rvi
allohsct
recipi
verifi
isirsv
applic
patient
rsv
addit
influenza
adv
hpiv
rvi
predict
risk
develop
pneumonia
find
use
beyond
clinic
manag
may
also
use
stratif
clinic
trial
novel
antivir
document
high
associ
hrhv
hcov
pneumonia
high
incid
pneumonia
caus
rvi
nonneglig
incid
need
mechan
ventil
death
testifi
unmet
need
effect
antivir
therapi
rvi
group
immunocompromis
host
